Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    CARE-MS
Show Display Options
Rank Status Study
1 Completed Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies
Condition: Multiple Sclerosis
Intervention:
2 Completed
Has Results
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab;   Biological: Interferon beta-1a
3 Completed
Has Results
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab 12 mg;   Biological: Alemtuzumab 24 mg;   Biological: Interferon beta-1a
4 Completed An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: alemtuzumab
5 Terminated Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor
Condition: Multiple Sclerosis (MS) - Relapsing-remitting
Intervention: Biological: sirolimus
6 Enrolling by invitation Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)
Condition: Relapsing Remitting Multiple Sclerosis
Intervention:

Study has passed its completion date and status has not been verified in more than two years.